Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98


Lens cholesterol biosynthesis inhibition: A common mechanism of cataract formation in laboratory animals by pharmaceutical products.

Aleo MD, Doshna CM, Baltrukonis D, Fortner JH, Drupa CA, Navetta KA, Fritz CA, Potter DM, Verdugo ME, Beierschmitt WP.

J Appl Toxicol. 2019 Sep;39(9):1348-1361. doi: 10.1002/jat.3822. Epub 2019 Jun 24.


Liver safety evaluation of endothelin receptor antagonists using HepatoPac® : A single model impact assessment on hepatocellular health, function and bile acid disposition.

Aleo MD, Ukairo O, Moore A, Irrechukwu O, Potter DM, Schneider RP.

J Appl Toxicol. 2019 Aug;39(8):1192-1207. doi: 10.1002/jat.3805. Epub 2019 May 27.


Cardiac sodium channel antagonism - Translation of preclinical in vitro assays to clinical QRS prolongation.

Jenkinson S, Bassyouni A, Cordes J, Fermini B, Guo D, Potter DM, Ramirez DS, Steidl-Nichols J, Sun S, Wisialowski T.

J Pharmacol Toxicol Methods. 2018 Jan - Feb;89:9-18. doi: 10.1016/j.vascn.2017.10.002. Epub 2017 Oct 16.


Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database.

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, Kadambi VJ.

Toxicol Appl Pharmacol. 2017 Nov 1;334:100-109. doi: 10.1016/j.taap.2017.09.006. Epub 2017 Sep 8.


Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.

Chapin RE, Ball DJ, Radi ZA, Kumpf SW, Koza-Taylor PH, Potter DM, Mark Vogel W.

Toxicol Sci. 2017 Jan;155(1):148-156. doi: 10.1093/toxsci/kfw197. Epub 2016 Oct 5.


Application of Novel Software Algorithms to Spectral-Domain Optical Coherence Tomography for Automated Detection of Diabetic Retinopathy.

Adhi M, Semy SK, Stein DW, Potter DM, Kuklinski WS, Sleeper HA, Duker JS, Waheed NK.

Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):410-7. doi: 10.3928/23258160-20160419-03.


Alternative schedules of levothyroxine administration.

Geer M, Potter DM, Ulrich H.

Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. Review.


Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS.

Clin Cancer Res. 2015 Jan 15;21(2):286-94. doi: 10.1158/1078-0432.CCR-14-1790. Epub 2014 Nov 25.


Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet.

Singh RK, Joshi SM, Potter DM, Leber SM, Carlson MD, Shellhaas RA.

Pediatrics. 2014 Nov;134(5):e1431-5. doi: 10.1542/peds.2013-3106.


Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H.

J Clin Oncol. 2014 Jul 1;32(19):2050-8. doi: 10.1200/JCO.2013.54.0526. Epub 2014 Jun 2.


Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.

Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.

Hepatology. 2014 Sep;60(3):1015-22. doi: 10.1002/hep.27206. Epub 2014 Jul 14.


Effects of lersivirine on canine and rodent thyroid function.

Houle CD, Finch GL, Mauthe RJ, Potter DM, Walisser JA, Gardner IB, DeWit RH.

Toxicol Pathol. 2014 Jul;42(5):897-912. doi: 10.1177/0192623313503516. Epub 2013 Oct 16.


Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.

Van Buren G 2nd, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, Moser AJ.

Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1.


A translational pharmacology approach to understanding the predictive value of abuse potential assessments.

Horton DB, Potter DM, Mead AN.

Behav Pharmacol. 2013 Sep;24(5-6):410-36. doi: 10.1097/FBP.0b013e3283644d2e. Review.


LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H.

Clin Cancer Res. 2013 Apr 1;19(7):1816-26. doi: 10.1158/1078-0432.CCR-12-2861. Epub 2013 Feb 11.


MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ.

Cancer Prev Res (Phila). 2013 Jan;6(1):18-26. doi: 10.1158/1940-6207.CAPR-12-0275. Epub 2012 Dec 17.


Ultrasound-guided angioplasty of autogenous arteriovenous fistulas in the office setting.

Gorin DR, Perrino L, Potter DM, Ali TZ.

J Vasc Surg. 2012 Jun;55(6):1701-5. doi: 10.1016/j.jvs.2011.12.016. Epub 2012 Jan 23. Erratum in: J Vasc Surg. 2012 Nov;56(5):1488.


Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients.

Potter DM, Butterfield LH, Divito SJ, Sander CA, Kirkwood JM.

J Immunol Methods. 2012 Feb 28;376(1-2):108-12. doi: 10.1016/j.jim.2011.12.003. Epub 2011 Dec 21.


Multiplex serum biomarker assessments: technical and biostatistical issues.

Butterfield LH, Potter DM, Kirkwood JM.

J Transl Med. 2011 Oct 11;9:173. doi: 10.1186/1479-5876-9-173.


A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.

Sehgal R, Lembersky BC, Rajasenan KK, Crandall TL, Balaban EP, Pinkerton RA, Kane P, Schmotzer A, Zeh H, Potter DM, Ramanathan RK.

Clin Colorectal Cancer. 2011 Jun;10(2):117-20. doi: 10.1016/j.clcc.2011.03.008. Epub 2011 Apr 28.


Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N.

Clin Colorectal Cancer. 2012 Mar;11(1):53-9. doi: 10.1016/j.clcc.2011.05.003. Epub 2011 Aug 2.


Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.


Histologic and cytologic detection of endocrine and reproductive tract effects of exemestane in female rats treated for up to twenty-eight days.

Mirsky ML, Sivaraman L, Houle C, Potter DM, Chapin RE, Cappon GD.

Toxicol Pathol. 2011 Jun;39(4):589-605. doi: 10.1177/0192623311402220. Epub 2011 May 2.


Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.

Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC.

Neurology. 2011 Jan 18;76(3):265-72. doi: 10.1212/WNL.0b013e318207b031.


Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS.

J Clin Oncol. 2011 Jan 20;29(3):330-6. doi: 10.1200/JCO.2010.30.7744. Epub 2010 Dec 13.


A fluorinated dendrimer-based nanotechnology platform: new contrast agents for high field imaging.

Huang Z, Sengar RS, Nigam A, Abadjian MC, Potter DM, Grotjahn DB, Wiener EC.

Invest Radiol. 2010 Oct;45(10):641-54. doi: 10.1097/RLI.0b013e3181ee6e06.


Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate.

Warin R, Chambers WH, Potter DM, Singh SV.

Cancer Res. 2009 Dec 15;69(24):9473-80. doi: 10.1158/0008-5472.CAN-09-2960.


Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.

Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H.

Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10746-51. doi: 10.1073/pnas.0811817106. Epub 2009 Jun 11.


Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer.

Silk AW, Schoen RE, Potter DM, Finn OJ.

Mol Immunol. 2009 Nov;47(1):52-6. doi: 10.1016/j.molimm.2008.12.025. Epub 2009 Feb 13.


A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.


A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.

Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM, Bartlett DL.

Ann Surg Oncol. 2009 Feb;16(2):385-94. doi: 10.1245/s10434-008-0179-5. Epub 2008 Nov 25.


Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice.

Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, Hahm ER, Marynowski SW, Bommareddy A, Potter DM, Dhir R.

Cancer Res. 2008 Nov 15;68(22):9503-11. doi: 10.1158/0008-5472.CAN-08-1677.


A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.

Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM, Ivy SP, Belani CP.

Clin Cancer Res. 2008 Jun 1;14(11):3456-61. doi: 10.1158/1078-0432.CCR-07-5088.


Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH.

Cancer Immunol Immunother. 2009 Jan;58(1):121-33. doi: 10.1007/s00262-008-0533-2. Epub 2008 May 17.


Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.


Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP; National Cancer Institute Organ Dysfunction Working Group.

J Clin Oncol. 2008 Feb 1;26(4):563-9. doi: 10.1200/JCO.2007.11.0304.


Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.

Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF.

J Transl Med. 2007 Dec 19;5:67.


Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells.

Goding SR, Yang Q, Knudsen KB, Potter DM, Basse PH.

Hum Gene Ther. 2007 Aug;18(8):701-11.


Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H.

Cancer Res. 2007 Jul 1;67(13):6451-8.


Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.

Butterfield LH, Ribas A, Potter DM, Economou JS.

Cancer Immunol Immunother. 2007 Dec;56(12):1931-43. Epub 2007 May 24.


Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP.

Clin Cancer Res. 2007 Jun 15;13(12):3605-10. Epub 2007 May 17. Erratum in: Clin Cancer Res. 2007 Oct 15;13(20):6245. Ramananthan, Ramesh K [corrected to Ramanathan, Ramesh K].


AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Evdokimova VN, Liu Y, Potter DM, Butterfield LH.

J Immunother. 2007 May-Jun;30(4):425-37.


DNA repair pathways involved in anaphase bridge formation.

Acilan C, Potter DM, Saunders WS.

Genes Chromosomes Cancer. 2007 Jun;46(6):522-31.


Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.

Clin Cancer Res. 2007 Mar 15;13(6):1769-74.


Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

Potter DM.

J Biopharm Stat. 2006;16(5):579-604. Review.


Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis.

Kahlenborn C, Modugno F, Potter DM, Severs WB.

Mayo Clin Proc. 2006 Oct;81(10):1290-302.


Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.

Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH.

J Immunol. 2006 Jul 1;177(1):712-21.


Omnibus permutation tests of the overall null hypothesis in datasets with many covariates.

Potter DM, Griffiths DJ.

J Biopharm Stat. 2006 May;16(3):327-41.


A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS.

Clin Cancer Res. 2006 May 1;12(9):2817-25.

Supplemental Content

Loading ...
Support Center